Exact Mass: 503.185
Exact Mass Matches: 503.185
Found 500 metabolites which its exact mass value is equals to given mass value 503.185
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
methyl (1S,2S,3R,5S,8R,9R,10R)-10-[(2R,3E,5E,7E)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-3,5,9-trimethyl-7-oxo-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylate
[(2S,3S,4S)-4,6-Diamino-3-hydroxy-1-[[(1S)-1-[(3S)-8-hydroxy-1-oxo-3,4-dihydroisochromen-3-yl]-3-methylbutyl]amino]-1,6-dioxohexan-2-yl] dihydrogen phosphate
Gravacridonediol glucoside
Gravacridonediol glucoside is found in herbs and spices. Gravacridonediol glucoside is an alkaloid from Ruta graveolens (rue
beta-D-Galactopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->6)-D-mannose
beta-D-Galactopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->6)-D-mannose is a constituent of blood group substance of human milk. Constituent of blood group substance of human milk
N-(4-Acetylphenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists MRS-1706 is a potent and selective adenosine A2B receptor inverse agonist. MRS-1706 has Ki values of 1.39, 112, 157, and 230 nM for human A2B, A2A, A1 and A3 receptors respectively. MRS-1706 blocks adenosine-mediated cAMP induction[1][2].
Naloxone-3-glucuronide
(3aS)-5c-[(1R,2E,4E)-6-((E)-2,4-dioxo-pyrrolidin-3-ylidene)-6-hydroxy-1,3-dimethyl-hexa-2,4-dienyl]-2c,6t,9a-trimethyl-8-oxo-(9at)-octahydro-3ar,7c-epioxido-furo[3,2-b]oxocine-3c-carboxylic acid methyl ester|antibiotic Bu-2313-B|nocamycin-I
{(2R)-2-[alpha-D-glucopyranosyl(1->6)beta-D-glucopyranosyloxy]-2-(3-hydroxy-4-methoxyphenyl)}acetonitrile
Nocamycin I
An organic heterotricyclic compound and tetramic acid derivative originally isolated from an unidentified oligosporic actinomycete strain (no. E864-861) and found to be active against both Gram-positive and Gram-negative anaerobic bacteria as well as some aerobic bacteria such as Streptococci. The methyl ester of nocamycin E.
Glu Val Gln Glu
Glu Gln Val Glu
Ala Glu Glu Arg
Ala Glu Arg Glu
Ala His Asn Tyr
Ala His Tyr Asn
Ala Met Pro Trp
Ala Met Trp Pro
Ala Asn His Tyr
Ala Asn Asn Trp
Ala Asn Trp Asn
Ala Asn Tyr His
Ala Pro Met Trp
Ala Pro Trp Met
Ala Arg Glu Glu
Ala Trp Met Pro
Ala Trp Asn Asn
Ala Trp Pro Met
Ala Tyr His Asn
Ala Tyr Asn His
Cys Glu Pro Arg
Cys Glu Arg Pro
Cys His Met Asn
Cys His Asn Met
Cys Met His Asn
Cys Met Asn His
Cys Asn His Met
Cys Asn Met His
Cys Pro Glu Arg
Cys Pro Arg Glu
Cys Pro Val Trp
Cys Pro Trp Val
Cys Arg Glu Pro
Cys Arg Pro Glu
Cys Val Pro Trp
Cys Val Trp Pro
Cys Trp Pro Val
Cys Trp Val Pro
Asp Asp Arg Val
Asp Asp Val Arg
Asp Glu Ile Gln
Asp Glu Leu Gln
Asp Glu Gln Ile
Asp Glu Gln Leu
Asp Ile Glu Gln
Asp Ile Gln Glu
Asp Lys Asn Gln
Asp Lys Gln Asn
Asp Leu Glu Gln
Asp Leu Gln Glu
Asp Asn Lys Gln
Asp Asn Gln Lys
Asp Asn Gln Gln
Asp Pro Ser Trp
Asp Pro Trp Ser
Asp Gln Glu Ile
Asp Gln Glu Leu
Asp Gln Ile Glu
Asp Gln Lys Asn
Asp Gln Leu Glu
Asp Gln Asn Lys
Asp Gln Asn Gln
Asp Gln Gln Asn
Asp Arg Asp Val
Asp Arg Val Asp
Asp Ser Pro Trp
Asp Ser Trp Pro
Asp Val Asp Arg
Asp Val Arg Asp
Asp Trp Pro Ser
Asp Trp Ser Pro
Glu Ala Glu Arg
Glu Ala Arg Glu
Glu Cys Pro Arg
Glu Cys Arg Pro
Glu Asp Ile Gln
Glu Asp Leu Gln
Glu Asp Gln Ile
Glu Asp Gln Leu
Glu Glu Ala Arg
Glu Glu Ile Asn
Glu Glu Leu Asn
Glu Glu Asn Ile
Glu Glu Asn Leu
Glu Glu Gln Val
Glu Glu Arg Ala
Glu Glu Val Gln
Glu Ile Asp Gln
Glu Ile Glu Asn
Glu Ile Asn Glu
Glu Ile Gln Asp
Glu Lys Asn Asn
Glu Leu Asp Gln
Glu Leu Glu Asn
Glu Leu Asn Glu
Glu Leu Gln Asp
Glu Met Pro Gln
Glu Met Gln Pro
Glu Asn Glu Ile
Glu Asn Glu Leu
Glu Asn Ile Glu
Glu Asn Lys Asn
Glu Asn Leu Glu
Glu Asn Asn Lys
Glu Asn Asn Gln
Glu Asn Gln Asn
Glu Pro Cys Arg
Glu Pro Met Gln
Glu Pro Gln Met
Glu Pro Arg Cys
Glu Gln Asp Ile
Glu Gln Asp Leu
Glu Gln Glu Val
Glu Gln Ile Asp
Glu Gln Leu Asp
Glu Gln Met Pro
Glu Gln Asn Asn
Glu Gln Pro Met
Glu Arg Ala Glu
Glu Arg Cys Pro
Glu Arg Glu Ala
Glu Arg Pro Cys
Glu Val Glu Gln
Phe His Asn Ser
Phe His Ser Asn
Phe Asn His Ser
Phe Asn Ser His
Phe Ser His Asn
Phe Ser Asn His
Gly His Gln Tyr
Gly His Tyr Gln
Gly Asn Gln Trp
Gly Asn Trp Gln
Gly Gln His Tyr
Gly Gln Asn Trp
Gly Gln Trp Asn
Gly Gln Tyr His
Gly Trp Asn Gln
Gly Trp Gln Asn
Gly Tyr His Gln
Gly Tyr Gln His
His Ala Asn Tyr
His Ala Tyr Asn
His Cys Met Asn
His Cys Asn Met
His Phe Asn Ser
His Phe Ser Asn
His Gly Gln Tyr
His Gly Tyr Gln
His His Asn Pro
His His Pro Asn
His Met Cys Asn
His Met Asn Cys
His Asn Ala Tyr
His Asn Cys Met
His Asn Phe Ser
His Asn His Pro
His Asn Met Cys
His Asn Pro His
His Asn Ser Phe
His Asn Tyr Ala
His Pro His Asn
His Pro Asn His
His Gln Gly Tyr
His Gln Tyr Gly
His Ser Phe Asn
His Ser Asn Phe
His Tyr Ala Asn
His Tyr Gly Gln
His Tyr Asn Ala
His Tyr Gln Gly
Ile Asp Glu Gln
Ile Asp Gln Glu
Ile Glu Asp Gln
Ile Glu Glu Asn
Ile Glu Asn Glu
Ile Glu Gln Asp
Ile Asn Glu Glu
Ile Gln Asp Glu
Ile Gln Glu Asp
Leu Asp Glu Gln
Leu Asp Gln Glu
Leu Glu Asp Gln
Leu Glu Glu Asn
Leu Glu Asn Glu
Leu Glu Gln Asp
Leu Asn Glu Glu
Leu Gln Asp Glu
Leu Gln Glu Asp
Met Ala Pro Trp
Met Ala Trp Pro
Met Cys His Asn
Met Cys Asn His
Met Glu Pro Gln
Met Glu Gln Pro
Met His Cys Asn
Met His Asn Cys
Met Asn Cys His
Met Asn His Cys
Met Pro Ala Trp
Met Pro Glu Gln
Met Pro Gln Glu
Met Pro Trp Ala
Met Gln Glu Pro
Met Gln Pro Glu
Met Trp Ala Pro
Met Trp Pro Ala
Asn Ala His Tyr
Asn Ala Asn Trp
Asn Ala Trp Asn
Asn Ala Tyr His
Asn Cys His Met
Asn Cys Met His
Asn Asp Gln Gln
Asn Glu Glu Ile
Asn Glu Glu Leu
Asn Glu Ile Glu
Asn Glu Leu Glu
Asn Glu Asn Gln
Asn Glu Gln Asn
Asn Phe His Ser
Asn Phe Ser His
Asn Gly Gln Trp
Asn Gly Trp Gln
Asn His Ala Tyr
Asn His Cys Met
Asn His Phe Ser
Asn His His Pro
Asn His Met Cys
Asn His Pro His
Asn His Ser Phe
Asn His Tyr Ala
Asn Ile Glu Glu
Asn Leu Glu Glu
Asn Met Cys His
Asn Met His Cys
Asn Asn Ala Trp
Asn Asn Glu Gln
Asn Asn Gln Glu
Asn Asn Trp Ala
Asn Pro His His
Asn Gln Asp Gln
Asn Gln Glu Asn
Asn Gln Gly Trp
Asn Gln Asn Glu
Asn Gln Gln Asp
Asn Gln Trp Gly
Asn Ser Phe His
Asn Ser His Phe
Asn Trp Ala Asn
Asn Trp Gly Gln
Asn Trp Asn Ala
Asn Trp Gln Gly
Asn Tyr Ala His
Asn Tyr His Ala
Pro Ala Met Trp
Pro Ala Trp Met
Pro Cys Glu Arg
Pro Cys Arg Glu
Pro Cys Val Trp
Pro Cys Trp Val
Pro Asp Ser Trp
Pro Asp Trp Ser
Pro Glu Cys Arg
Pro Glu Met Gln
Pro Glu Gln Met
Pro Glu Arg Cys
Pro His His Asn
Pro His Asn His
Pro Met Ala Trp
Pro Met Glu Gln
Pro Met Gln Glu
Pro Met Trp Ala
Pro Asn His His
Pro Gln Glu Met
Pro Gln Met Glu
Pro Arg Cys Glu
Pro Arg Glu Cys
Pro Ser Asp Trp
Pro Ser Trp Asp
Pro Val Cys Trp
Pro Val Trp Cys
Pro Trp Ala Met
Pro Trp Cys Val
Pro Trp Asp Ser
Pro Trp Met Ala
Pro Trp Ser Asp
Pro Trp Val Cys
Gln Asp Glu Ile
Gln Asp Glu Leu
Gln Asp Ile Glu
Gln Asp Leu Glu
Gln Asp Asn Gln
Gln Asp Gln Asn
Gln Glu Asp Ile
Gln Glu Asp Leu
Gln Glu Glu Val
Gln Glu Ile Asp
Gln Glu Leu Asp
Gln Glu Met Pro
Gln Glu Asn Asn
Gln Glu Pro Met
Gln Glu Val Glu
Gln Gly His Tyr
Gln Gly Asn Trp
Gln Gly Trp Asn
Gln Gly Tyr His
Gln His Gly Tyr
Gln His Tyr Gly
Gln Ile Asp Glu
Gln Ile Glu Asp
Gln Leu Asp Glu
Gln Leu Glu Asp
Gln Met Glu Pro
Gln Met Pro Glu
Gln Asn Asp Gln
Gln Asn Glu Asn
Gln Asn Gly Trp
Gln Asn Asn Glu
Gln Asn Gln Asp
Gln Asn Trp Gly
Gln Pro Glu Met
Gln Pro Met Glu
Gln Gln Asp Asn
Gln Gln Asn Asp
Gln Val Glu Glu
Gln Trp Gly Asn
Gln Trp Asn Gly
Gln Tyr Gly His
Gln Tyr His Gly
Arg Cys Glu Pro
Arg Cys Pro Glu
Arg Glu Cys Pro
Arg Glu Pro Cys
Arg Pro Cys Glu
Arg Pro Glu Cys
Ser Asp Pro Trp
Ser Asp Trp Pro
Ser Phe His Asn
Ser Phe Asn His
Ser His Phe Asn
Ser His Asn Phe
Ser Asn Phe His
Ser Asn His Phe
Ser Pro Asp Trp
Ser Pro Trp Asp
Ser Trp Asp Pro
Ser Trp Pro Asp
Val Cys Pro Trp
Val Cys Trp Pro
Val Glu Glu Gln
Val Glu Gln Glu
Val Pro Cys Trp
Val Pro Trp Cys
Val Gln Glu Glu
Val Trp Cys Pro
Val Trp Pro Cys
Trp Ala Met Pro
Trp Ala Asn Asn
Trp Ala Pro Met
Trp Cys Pro Val
Trp Cys Val Pro
Trp Asp Pro Ser
Trp Asp Ser Pro
Trp Gly Asn Gln
Trp Gly Gln Asn
Trp Met Ala Pro
Trp Met Pro Ala
Trp Asn Ala Asn
Trp Asn Gly Gln
Trp Asn Asn Ala
Trp Asn Gln Gly
Trp Pro Ala Met
Trp Pro Cys Val
Trp Pro Asp Ser
Trp Pro Met Ala
Trp Pro Ser Asp
Trp Pro Val Cys
Trp Gln Gly Asn
Trp Gln Asn Gly
Trp Ser Asp Pro
Trp Ser Pro Asp
Trp Val Cys Pro
Trp Val Pro Cys
Tyr Ala His Asn
Tyr Ala Asn His
Tyr Gly His Gln
Tyr Gly Gln His
Tyr His Ala Asn
Tyr His Gly Gln
Tyr His Asn Ala
Tyr His Gln Gly
Tyr Asn Ala His
Tyr Asn His Ala
Tyr Gln Gly His
Tyr Gln His Gly
Gravacridonediol glucoside
beta-D-Galactopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->6)-D-mannose
Rosuvastatin calcium
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM[2]. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3].
4-methoxyphenyl 4,6-o-benzylidene-2-deoxy-2-phthalimido-beta-d-glucopyranoside
Trimebutine Maleate
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D005765 - Gastrointestinal Agents Trimebutine maleate is an orally anti-tumor agent. Trimebutine maleate selectively suppresses stemness and proliferation of ovarian cancer stem cells (CSCs). Trimebutine maleate reduces the colonic muscle hypercontractility, modulates gastrointestinal motility, induces apoptosis and can be used for the research of glioma/glioblastoma and irritable bowel syndrome[1][2][3][4][5][6].
5,5,5′,5′,5′′,5′′-Hexamethyltris(1,2,3-Dioxaphosphorinanemethan)-Amin 2,2′,2′′-Trioxid
((hydroxy((2-(6-pivalaMido-9H-purin-9-yl)ethoxy)Methyl)phosphoryl)oxy)Methyl pivalate
4-Methylphenyl 2-O-(phenylmethyl)-1-thio-beta-D-galactopyranoside triacetate
4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide
3-(1h-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid
methyl (3R,5S,9R,10R)-10-[(2R,3E,5E,7Z)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-3,5,9-trimethyl-7-oxo-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylate
3-L-arginyl-AMP
An L-arginyl ester obtained by formal condensation of the carboxy group of L-arginine with the 3-hydroxy group of AMP.
(1R)-N-(3,5-dimethyl-4-isoxazolyl)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
2-[(2R,4aS,12aS)-8-(methanesulfonamido)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyphenyl)acetamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
2-[(3S,6aR,8S,10aR)-1-(4-chlorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide
[(1S)-2-[(3-chlorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
2-[(3R,6aR,8S,10aR)-1-(4-chlorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide
[(1R)-2-[(3-chlorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(1S)-N-(3,5-dimethyl-4-isoxazolyl)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
4-[7-[Ethyl(5-carboxypentyl)amino]-2-oxo-2H-1-benzopyran-3-yl]-1-(3-sulfonatopropyl)pyridinium
YH239-EE
YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent. IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction. YH239-EE induces cell cycle arrest and causes potent cell apoptosis via activation of p53 and downstream targets in four AML cells (OCI-AML-3 and MOLM-13 with wt p53, NB4 with p53 mutation, and HL60 with p53 deletion).